Business
Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress
Tecarfarin is the only known Novel Vitamin K Antagonist in Development PONTE VEDRA, Fla., Sept. 5, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq:
About this update from Cadrenal Therapeutics, Inc.
[{"type":"text","content":"Tecarfarin is the only known Novel Vitamin K Antagonist in Development\nPONTE VEDRA, Fla., Sept. 5, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today cited recent data that underscores additional need for an improved Vitamin K Antagonist (VKA). The Company believes tecarfarin is the solution for this unmet need.\n\n \n \n \n \n \n \n\n \nAt the recent European Society of Cardiology Congress (ESC) in Amsterdam, The Netherlands, the open-label \"FRAIL-AF\" trial was presented, revealing that switching International Normalized Ratio (INR)-guided VKA treatment to direct oral anticoagulants (DOACs aka NOACs) in frail older patients with Atrial Fibrillation (AFib) was associated with more bleeding complications compared to continuing VKA treatment, without an associated reduction in thromboembolic complications. Reports indicate that this unique trial was stopped early for futility in seeking superiority for the direct oral anticoagulant (DOAC) strategy. FRAIL-AF was deemed the most important study from ESC, according to Medscape.\nIn the report, study author Geert-Jan Geersing, MD, PhD, of the University Medical Center Utrecht in the Netherlands, at the ESC Congress concluded that \"Switching from a VKA to a NOAC should not be considered without a clear indication in frail older patients with AFib.\"\nCadrenal is developing tecarfarin, a novel Vitamin K Antagonist, targeted for indications where existing VKAs fail to achieve sufficiently stable anticoagulation and DOACs (Eliquis-class drugs) are not widely prescribed.\n\"The findings of the FRAIL-AF study highlight the benefits of VKAs compared to DOACs in an additional unique patient population,\" commented Quang Pham, CEO of Cadrenal Therapeutics. \"Tecarfarin, an enhanced VKA, avoids the existing metabolism problems of currently available VKAs by using an alternate metabolic pathway. We believe tecarfarin will provide improved outcomes for patients with certain rare medical conditions. Cadrenal has identified three such rare medical conditions: End-Stage Kidney Disease (ESKD) with Atrial Fibrillation (AFib); Left Ventricu...